VMD-928 Tablet and Pembrolizumab (200 mg)

6 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Treatments and conditions

VMD-928 Tablet and Pembrolizumab (200 mg)
Treatment and conditionWhere it standsTrials
VMD-928 Tablet and Pembrolizumab (200 mg) for carcinoma, adenoid cysticPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VMD-928 Tablet and Pembrolizumab (200 mg) for laryngeal diseasesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VMD-928 Tablet and Pembrolizumab (200 mg) for mesotheliomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VMD-928 Tablet and Pembrolizumab (200 mg) for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VMD-928 Tablet and Pembrolizumab (200 mg) for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VMD-928 Tablet and Pembrolizumab (200 mg) for tracheal diseasesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1